LAVAL, QC, April 20 /PRNewswire-FirstCall/ - Neurochem Inc. announced today that on Tuesday, April 25, 2006, Dr. Francesco Bellini, Chairman, President and CEO, will present Neurochem's overall strategy and progress to date at the UBS Global Specialty Pharmaceuticals Conference to be held at the Grand Hyatt New York, in New York (N.Y.). The presentation will take place at 10:30 A.M. ET, in Ballroom C. Following Dr. Bellini's speech, the corporate presentation will be available on the Company's website at http://www.neurochem.com/Investor.htm(pound sign)Presentation.
A live audio Web cast of Neurochem's presentation can be accessed at www.ibb.ubs.com. A replay of the presentation will begin 3 hours after the actual presentation time, and will be available until May 25, 2006.
Dr. Bellini will also present an update on the Company's activities at the Sixth Annual Fortis Bank Biotechnology Conference on Wednesday, April 26, 2006, at The Four Seasons Hotel, Park Lane, in London (U.K.). The presentation will take place at 11:15 A.M. GMT, in Ballroom A, and will be available on the Company's website.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (Fibrillex(TM)) is designated as an orphan drug, is a Fast Track product candidate and is also part of FDA Continuous Marketing Application Pilot 1 and Pilot 2 programs. The FDA designated the eprodisate (Fibrillex(TM)) new drug application for priority review. Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease, is currently in Phase III clinical trials in both North America and Europe, and tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward- looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.
CONTACT: Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4573, lhebert@neurochem.com
NEUROCHEM INC.CONTACT: Lise Hebert, PhD, Vice President, Corporate Communications, (450)680-4573, lhebert@neurochem.com
